MA55084A - Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau - Google Patents
Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peauInfo
- Publication number
- MA55084A MA55084A MA055084A MA55084A MA55084A MA 55084 A MA55084 A MA 55084A MA 055084 A MA055084 A MA 055084A MA 55084 A MA55084 A MA 55084A MA 55084 A MA55084 A MA 55084A
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- administration
- treatment
- skin cancer
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811827P | 2019-02-28 | 2019-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55084A true MA55084A (fr) | 2022-01-05 |
Family
ID=70057261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055084A MA55084A (fr) | 2019-02-28 | 2020-02-27 | Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220259313A1 (fr) |
| EP (1) | EP3930848A1 (fr) |
| JP (2) | JP2022521800A (fr) |
| KR (1) | KR20210134690A (fr) |
| CN (1) | CN113490529A (fr) |
| AU (1) | AU2020228296B2 (fr) |
| CA (1) | CA3137361A1 (fr) |
| IL (1) | IL285050A (fr) |
| MA (1) | MA55084A (fr) |
| MX (1) | MX2021010228A (fr) |
| SG (1) | SG11202108089SA (fr) |
| WO (1) | WO2020176699A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| ES2954153T3 (es) | 2015-12-22 | 2023-11-20 | Regeneron Pharma | Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer |
| WO2020118208A1 (fr) | 2018-12-07 | 2020-06-11 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Procédé de détermination du risque de développement du cancer de la peau et de prévention thérapeutique du cancer de la peau par mesure des membres de la voie de signalisation pd-1/pd-l1 |
| CN117043193A (zh) * | 2021-02-11 | 2023-11-10 | 瑞泽恩制药公司 | 通过施用新辅助pd-1抑制剂治疗癌症的方法 |
| US20250346670A1 (en) * | 2021-02-11 | 2025-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor |
| WO2024186917A2 (fr) * | 2023-03-06 | 2024-09-12 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions pour l'inhibition de pd-l1 et leurs procédés d'utilisation |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (fr) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010036959A2 (fr) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US8686119B2 (en) | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| ES2742379T3 (es) | 2012-05-31 | 2020-02-14 | Hoffmann La Roche | Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201901057UA (en) | 2014-08-05 | 2019-03-28 | Cb Therapeutics Inc | Anti-pd-l1 antibodies |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CN108495651A (zh) * | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| ES2954153T3 (es) * | 2015-12-22 | 2023-11-20 | Regeneron Pharma | Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer |
| IL261998B2 (en) | 2016-04-07 | 2023-03-01 | Chemocentryx Inc | Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| TWI822521B (zh) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| CN117442719A (zh) * | 2017-02-21 | 2024-01-26 | 瑞泽恩制药公司 | 用于治疗肺癌的抗pd-1抗体 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
-
2020
- 2020-02-27 SG SG11202108089SA patent/SG11202108089SA/en unknown
- 2020-02-27 CA CA3137361A patent/CA3137361A1/fr active Pending
- 2020-02-27 JP JP2021550167A patent/JP2022521800A/ja active Pending
- 2020-02-27 AU AU2020228296A patent/AU2020228296B2/en active Active
- 2020-02-27 MX MX2021010228A patent/MX2021010228A/es unknown
- 2020-02-27 KR KR1020217030808A patent/KR20210134690A/ko active Pending
- 2020-02-27 CN CN202080017060.8A patent/CN113490529A/zh active Pending
- 2020-02-27 EP EP20715554.0A patent/EP3930848A1/fr active Pending
- 2020-02-27 US US17/433,003 patent/US20220259313A1/en active Pending
- 2020-02-27 WO PCT/US2020/020018 patent/WO2020176699A1/fr not_active Ceased
- 2020-02-27 MA MA055084A patent/MA55084A/fr unknown
-
2021
- 2021-07-22 IL IL285050A patent/IL285050A/en unknown
-
2024
- 2024-12-20 JP JP2024225122A patent/JP2025041768A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210134690A (ko) | 2021-11-10 |
| EP3930848A1 (fr) | 2022-01-05 |
| JP2022521800A (ja) | 2022-04-12 |
| WO2020176699A1 (fr) | 2020-09-03 |
| AU2020228296B2 (en) | 2025-10-02 |
| JP2025041768A (ja) | 2025-03-26 |
| CN113490529A (zh) | 2021-10-08 |
| MX2021010228A (es) | 2021-10-26 |
| SG11202108089SA (en) | 2021-08-30 |
| AU2020228296A1 (en) | 2021-10-14 |
| US20220259313A1 (en) | 2022-08-18 |
| CA3137361A1 (fr) | 2020-09-03 |
| IL285050A (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52575A (fr) | Pansement pour le traitement de la peau endommagée | |
| MA56050A (fr) | Inhibiteurs hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| MA52232A (fr) | Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer | |
| MA54609A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| MA55959A (fr) | Dosage d'inhibiteur de kras pour le traitement de cancers | |
| MA54608A (fr) | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer | |
| EP3641829A4 (fr) | Promédicament d'interféron pour le traitement du cancer | |
| MA47310A (fr) | Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer | |
| EP3946357A4 (fr) | Formulations topiques pour le traitement de neuropathies périphériques | |
| EP3950686A4 (fr) | Dérivés d'amide n-hétéroaromatiques destinés au traitement du cancer | |
| EP3790867A4 (fr) | Inhibiteurs de kdm1a pour le traitement d'une maladie | |
| EP3737376A4 (fr) | Inhibiteurs sélectifs d'histone déacétylase pour le traitement d'une maladie humaine | |
| EP3883553A4 (fr) | Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau | |
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| EP3947460A4 (fr) | Agents multispécifiques pour le traitement du cancer | |
| EP3883552A4 (fr) | Composés cyanoaryl-aniline pour le traitement d'affections de la peau | |
| EP3664812A4 (fr) | Compositions topiques pour la peau destinées au traitement de l'érythème ou de l'inflammation cutanée | |
| EP3672587A4 (fr) | Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques | |
| EP3347010A4 (fr) | Synthèse et composition d'agents thérapeutiques photodynamiques pour le traitement ciblé du cancer | |
| EP3911313A4 (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
| EP3426254A4 (fr) | Utilisation d'inhibiteurs de braf pour le traitement de réactions cutanées | |
| EP3400942A4 (fr) | Utilisation de dérivés de quinoléine pour le traitement du cancer de l' sophage et procédé de traitement, composition pharmaceutique et trousse associée | |
| IL285050A (en) | Administering PD-1 inhibitors for the treatment of skin cancer | |
| EP3883567A4 (fr) | Composés naphthyridinone-aniline destinés au traitement d'affections de la peau | |
| EP3610850A4 (fr) | Composition d'agent nettoyant pour la peau |